Paquinimod, also known as ABR 215757, is a targeted and orally administered inhibitor of S100A8/S100A9. It effectively alleviates pneumonia and significantly lowers viral counts in mice infected with SARS-CoV-2[1][2][3].
Paquinimod 动物研究
Animal study
S100A9, a member of the S100 calcium-binding protein family, interacts with TLR-4. Paquinimod, which acts as an immunomodulatory agent, inhibits this interaction. The use of Paquinimod as a preventive measure lessens the severity of disease in experimental models of collagenase-induced osteoarthritis[1]. Paquinimod effectively prevents the onset of insulitis and diabetes in NOD mice. In a study to evaluate Paquinimod's preventive impact on diabetes in female NOD mice, various groups received daily Paquinimod doses of 0.04, 0.2, 1, and 5 mg/kg from the age of 10 weeks to 20 weeks. Glycosuria levels were monitored weekly from the 10th week to the study's conclusion at 40 weeks. The results showed a distinct dose-responsive decrease in the incidence of diabetes among the mice treated with Paquinimod[2].
搜索
